Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESB1609 formulation comparison and CYP2C9 interaction pharmacokinetics study
NL-OMON51356Active, not recruiting
- Sponsor
- ESCAPE Bio, Inc.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ESB1609 in Niemann-Pick disease type C (NPC) (3 arms), sponsored by ESCAPE Bio, Inc. Primary endpoints: ESB1609 pharmacokinetic parameters for formulation comparison, Effect of fluconazole on ESB1609 pharmacokinetics and 1 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
ESB1609
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NL-OMON51356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51356.